PDE-5 INHIBITORS AND CARDIAC HEALTH SYMPOSIUM 2023

[madman]

Princeton4 - 2023

www.eventdex.com

Burnett, Mulhall, Goldstein, Parish, and Kim!

 

[madman]

If you are interested in watching the lectures!

Cardiovascular Safety and Benefits of PDE-5 Inhibition in Women with Female Sexual Dysfunction (FSD): Summary of Findings from Clinical Trials of PDE-5 Inhibition in Women

Speaker Name and Title: Irwin Goldstein MD The Princeton 4 meeting was sponsored by an unrestricted grant from Sanofi. Sanofi was not involved in choosing the content or speakers for the meeting. Affiliation of the speaker: San Diego Sexual Medicine Alvarado Hospital, San Diego, CA University...

www.vumedi.com

Cardiovascular Safety and Benefits of PDE-5 Inhibition in Women with Female Sexual Dysfunction (FSD)

www.excelmale.com

Is ED an Independent Risk Factor or Risk Marker for CVD and What Is the Role of CT Calcium Scoring?

www.excelmale.com

Diagnostic and Treatment Guidelines for FSD in Women

www.excelmale.com

Erectile Dysfunction: Second and Third Line Therapies

www.excelmale.com

Update on the Psychological Impact of ED and ED Therapy

www.excelmale.com

Is There a Role for Topical or Oral PDE-5 Inhibition in Treating Female Sexual Dysfunction (FSD)?

www.excelmale.com

Are PDE-5 Inhibitors Cardioprotective?

www.excelmale.com

Safety of PDE-5 Inhibitors with Antihypertensive Medicines and Nitrates

www.excelmale.com

Mechanisms of Action of PDE-5 Inhibitors: Basic Science Concepts

www.excelmale.com

Do Younger Men with ED Have Greater Risk of Cardiovascular and All-Cause Mortality?

www.excelmale.com

Is the Princeton 3 Algorithm Still Correct, and What Is the Role of Telemedicine?

www.excelmale.com

Update on PDE-5 Inhibitors: Safety, New PDE-5 Inhibitors, Over-the-Counter PDE-5 Inhibitors?

"Princeton 4: PDE5 Inhibitors and Cardiac Health Symposium.” Selected lectures that examine the intersection between sexual health and cardiovascular health, with a focus on the pharmacologic therapy for erectile dysfunction (ED). Lectures from US experts on the newest data on safety and...

www.excelmale.com

 

[madman]

Long-term Effects of PDE5i on Cardiovascular Outcomes and Death

*This is the first meta-analysis to fully assess the long-term effects of PDE5i on hard cardiovascular endpoints. The major finding of our analysis is that the use of PDE5i is associated with a reduction of 22% in MACE and 30% in all-cause mortality primarily in middle-aged men with a rather...

www.excelmale.com

 

[madman]

Thread 'Tadalafil Use in Cardiovascular Disease'

Mar 2, 2025

Abstract

Tadalafil is a phosphodiesterase inhibitor currently approved for use in erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). While tadalafil’s benefits in ED and BPH have been well-established for years, its benefits in PAH were identified only recently in major clinical trials, resulting in the recent approval of a single tablet, combination therapy of tadalafil with an endothelin receptor antagonist for PAH. With Tadalafil’s cardiovascular benefits in ED, BPH, and PAH, clinical researchers have begun investigating...

• madman
• tadalafil; nitric oxide; cvd; ed; pah
• Replies: 5
• Forum: Health & Wellness